Pharmacology of dopamine agonists in the treatment of Parkinson's disease.
about
Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease.Elevated homocysteine by levodopa is detrimental to neurogenesis in parkinsonian modelA randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medicationsDopamine agonists in Parkinson's diseaseNormalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGEDouble-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease.Noradrenaline-induced release of newly-synthesized accumbal dopamine: differential role of alpha- and beta-adrenoceptors.In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.Dopamine agonists and neuroprotection in Parkinson's disease.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Dopamine agonists in the treatment of Parkinson's disease.Effects of aging and levodopa on the laryngeal adductor reflex in ratsConstant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease.Effects of dopamine D1 and D2 receptor antagonists on laryngeal neurophysiology in the rat.Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.Computational Study and Modified Design of Selective Dopamine D3 Receptor Agonists.Advances in dopamine receptor agonists for the treatment of Parkinson's disease.Neurotransmitters drive combinatorial multistate postsynaptic density networks.Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study.Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.Different risk-increasing drugs in recurrent versus single fallers: are recurrent fallers a distinct population?The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.Enzyme-Controlled Nanodevice for Acetylcholine-Triggered Cargo Delivery Based on Janus Au-Mesoporous Silica Nanoparticles.Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.
P2860
Q24815335-640DA815-8FBC-4EBC-9A8C-771F3825D059Q27334004-543219B3-E917-454B-AA13-D666DE595ACEQ28264401-70FE007B-FE8A-4BF0-8E54-063D0F2AEF1FQ28276692-40F0F8E5-C9A7-4A8B-BBE5-4FD328619B39Q33261647-EB4AB90D-D1A1-437E-87A2-CBA22A8B27D7Q34101796-B2A03C54-214A-47A7-9FD3-A8730E7095F4Q34171671-D11316B1-3EA2-4688-A140-4A29B149B85AQ34568923-A5622F4F-34A7-4D7A-A666-F899AD4E255EQ35015790-D3ED505B-ECA9-4859-B55B-E33CC6E3F28AQ35589979-6FD7606C-430B-46FC-A11B-7AD042A6F405Q36390870-9FD2CDF5-2273-4C2B-9F3E-2A0A5C6EF10CQ36761097-3BF78F5F-BFB7-4058-A208-CE5AD31A7569Q37016310-1C11229E-5D35-4E84-9ACE-D8D813343007Q37298742-21CEDFD6-D5C5-4DDA-91D2-ED4BDF5CE0C4Q38598375-BF542842-5797-459A-ADDE-55EC7B11CCC2Q38662579-5C905BF4-D2FD-4484-866E-98ECFE7B58A6Q38911479-EE5B9FBA-93D5-49ED-9B99-5ADD8B9D8BC7Q38937096-365F77C8-EB9A-468E-BEF2-690E8777D3DCQ41184685-EB5E165B-C59C-4A98-8960-933CE4AB8B39Q42077769-3ED7F9FB-80C3-412B-82CF-D6370530B5F7Q44436562-A297346B-13DE-402C-B369-9E12B04C79A5Q45749615-C2E2D5F2-6D38-41F4-B36D-7E2C32D5543EQ48164714-F0E86C6A-8D86-4FD7-913F-9808ECCCBC52Q53490437-5B34E7D1-579E-4D80-B71D-C314F5170237Q54328579-1D54E89D-0E64-4ED6-8D7E-1011B916DDE7
P2860
Pharmacology of dopamine agonists in the treatment of Parkinson's disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Pharmacology of dopamine agonists in the treatment of Parkinson's disease.
@ast
Pharmacology of dopamine agonists in the treatment of Parkinson's disease.
@en
Pharmacology of dopamine agonists in the treatment of Parkinson's disease.
@nl
type
label
Pharmacology of dopamine agonists in the treatment of Parkinson's disease.
@ast
Pharmacology of dopamine agonists in the treatment of Parkinson's disease.
@en
Pharmacology of dopamine agonists in the treatment of Parkinson's disease.
@nl
prefLabel
Pharmacology of dopamine agonists in the treatment of Parkinson's disease.
@ast
Pharmacology of dopamine agonists in the treatment of Parkinson's disease.
@en
Pharmacology of dopamine agonists in the treatment of Parkinson's disease.
@nl
P921
P1433
P1476
Pharmacology of dopamine agonists in the treatment of Parkinson's disease.
@en
P2093
Peter Jenner
P356
10.1212/WNL.58.SUPPL_1.S1
P407
P433
P577
2002-02-01T00:00:00Z